Iv Clinical Articles & Analysis
5 news found
Synbiotic Health has commercialized its first two Ecologically Advanced® probiotics: the clinically studied iVS-1® and the laboratory researched iVE-15® . Further clinical studies to demonstrate the health benefits of these novel ingredients are currently underway, with additional future studies planned for 2023 and ...
US Patent No. 9,861,805 B2 covers wide-ranging claims behind the needless connector for use in medical access devices such as IV catheters. “The patent issuance comes at an exciting time for our company, as many assets are evolving from speculative to tangible,” said founder and Chief Executive Officer Ryan Dennis, M.D. ...
” The group of New England clinicians described several ways that preventing IV dislodgement could improve clinical quality. Their responses included: Reducing IV restarts Less trauma to patients by reducing restart-related needlesticks Preserving patient veins for subsequent procedures Maintaining IV access in ...
Synbiotic Health is now commercializing its first two Ecologically Advanced® probiotics: the clinically studied iVS-1® and the laboratory researched iVE-15®. Both of these strains are in additional clinical studies during 2022 to demonstrate the health benefits of these novel ...
Rex Bionics is pleased to announce the commencement of the RAPPER IV Clinical trial at East Kent Hospitals University. RAPPER IV is a feasibility trial designed to evaluate a balance rehabilitation program enabled by REX in patients with Multiple Sclerosis. ...